Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : AbbVie
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 4 ans
A study to evaluate the safety and effect of three experimental drugs ABT-450, ABT-267, and ABT-333 in people with HCV. "Experimental" means that they have not been approved by any regulatory agency for sale to the public
The primary objectives of this study are to evaluate the safety of 12 weeks of treatment with ABT-450/r/ABT-267 and ABT-333 with and without RBV, and to show the non-inferiority in SVR12 rates (the pe...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 4 ans
Long-Term Safety and Tolerability of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: An Open-Label Extension Study for Subjects Completing Study M11-793
Evaluate the long-term safety and tolerability of ABT-126 in subjects with mild-to-moderate Alzheimer's disease (AD) taking doses of AChEIs in a 28-week open-label extension of Study M11-793.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 4 ans
A randomized, open-labeled study to evaluate the efficacy and safety of three experimental drugs (ABT-450, ABT-267 and ABT-333) compared with Telaprevir (a licenced product) in people with hepatitis C virus (HCV) who have not had treatment before. "Experimental" means that they have not been approved by any regulatory agency for sale to the public
The primary objectives of this study are to demonstrate that treatment with ABT-450/r/ABT-267 and ABT-333 administered with or without RBV has non-inferior efficacy (the percentage of subjects achiev...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 4 ans
A clinical trial to evaluate the safety and efficacy of multiple doses of ABT-719 to prevent acute kidney injury in patients undergoing high risk heart surgery
The study objective is to compare the safety and efficacy of doses of 800 mcg/kg, 1600 mcg/kg and 2100 mcg/kg intravenous (IV) infusions of ABT-719 to placebo in subjects who are at risk of AKI and un...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 4 ans
Long-Term Safety and Tolerability of ABT-126 in Subjects with Mild-to-Moderate Alzheimer’s Disease: An Open-Label Extension Study for Subjects Completing Study M10-985
The objective of this study is to evaluate the long-term safety and tolerability of ABT-126 in subjects with mild-to-moderate AD in a 28-week, open-label extension of Study M10-985.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 4 ans
A Phase 2b, Multicenter, Open-Label Study in Rheumatoid Arthritis Subjects who Completed Preceding Study M13-390 with Adalimumab
The study objective is to assess the long-term safety, tolerability, efficacy, and the immunogenicity of the 100 mg/mL adalimumab formulation.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme
Entre 18 ans
et 99 ans
AbbVie
MAJ Il y a 4 ans
Étude M15-394 : étude de phase 1 non-randomisée visant à évaluer la sûreté d’emploi et la pharmacocinétique de l’ABBV085 chez des patients ayant des tumeurs solides avancées. [essai clos aux inclusions]
L’ABBV-085 est un médicament biologique ayant une activité antitumorale potentielle. Après l’administration par voie intraveineuse, la partie de l’anticorps monoclonal cible et s’attache à l’antigène ...
Pays
France
Organes
Tumeurs solides
Spécialités
Immunothérapie - Vaccinothérapie
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 4 ans
A Phase 2 Study to Investigate the Safety and Efficacy of ABT-122 Given with Methotrexate in Subjects with Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
The primary objective is to estimate the treatment effect of ABT-122 by measuring the percentage of subjects achieving American College of Rheumatology response rates (ACR20) at Week 12 and to assess ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 4 ans
A Study to evaluate the effect and safety of experimental drugs ABT-493/ABT-530 in adults with Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
The primary objectives of this study are to are to compare the SVR12 rates (12-week sustained virologic response, SVR12 [HCV RNA < LLOQ 12 weeks following therapy]) of 8 or 12 weeks of treatment with ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 4 ans
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer
The primary objective of the study is to assess the incidence of pathological complete response (pCR) in breast and ipsilateral axillary tissue after daily treatment with veliparib in combination with...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
5
6
7
8
9
10
11
12
13
14
Suivant